SEARCH REQUEST FORM

Scientific and Technical Inf rmation Center

	30	cicitine and i centil	carrur rination CC	шсы	
	Requester's Full Name: Art Unit: 1644 Phone Mail Box and Bldg/Room Locatio	Number 30 🔏 - 😽	Examiner # :	oer: 18/871	1247
	-				- 10/11 - 11/11/11
	If more than one search is subn				******
٠.	Please provide a detailed statement of the Include the elected species or structures, lutility of the invention. Define any terms known. Please attach a copy of the cover	keywords, synonyms, acr s that may have a special i	onyms, and registry nun meaning. Give example	nbers, and combine with s or relevant citations, a	the concept or uthors, etc, if
	Title of Invention:	to a restain	ms & peptide	L F-18 X	ontra emis
	Title of Invention:	Y Protect	The state of the s	P	tomog
	inventors (piease provide aun names).			•	
	Farliest Priority Filing Date:	9/3/97			
•	Earliest Priority Filing Date:			an instead and and according	a) along with the
	For Sequence Searches Only Please inclu appropriate serial number.	iae au peruneni injormatioi	i (parent, cnua, atvistonat	, or issuea patent numbers) along with the
Ç.					
معر	Plean Sono	h attached	Claime 13	- 15.	•
	. *		. ,	1964	63IZ V1, 3,
			•		
			•		
		•			
			•		•
					r . Ž
	3iote	Jan Delaval Reference Librarian echnology & Chemical Libr CM1 1607 - 703-308-4498 jan.delaval@uspto.gov	ary		
				•	
			~		
	STAFF USE ONLY	Type of Search	Vendors a	**************************************	******* ole
	Searcher:	NA Sequence (#)	STN C	na cost where applicat	
	Searcher Phone #: 4498	AA Sequence (#)	Dialog		
	Searcher Location:	Structure (#)	Questel/Orbit		
	Date Searcher Picked Up: 8 1 2 / 02	Bibliographic	Dr.Link 3		
	Date Completed: \$\12\0\	Litigation		,	
	Searcher Prep & Review Time:	Fulltext	- Sequence Systems		
	Clerical Prep Time:	Patent Family	www/Internet	`	
	Online Time: 35	Other			
	PTO-1590 (8-01)				-
	10/0 (0 01)				

and the property of the proper

```
=> d his
```

```
(FILE 'REGISTRY' ENTERED AT 17:36:08 ON 12 AUG 2002)
                 DEL HIS
      FILE 'HCAPLUS' ENTERED AT 17:36:25 ON 12 AUG 2002
                 E US6187284/PN
 L1
               1 S E3
                 E US6358489/PN
 L2
               1 S E3
                 E US97-057485/AP, PRN
L3
               1 S E5
L4
               1 S L1-L3
                 SEL RN
      FILE 'REGISTRY' ENTERED AT 17:37:28 ON 12 AUG 2002
L5
              37 S E1-E37
L6
               3 S L5 AND SQL/FA
      FILE 'HCAPLUS' ENTERED AT 17:39:56 ON 12 AUG 2002
                 E GRIFFITHS G/AU
L7
             120 S E3, E12, E31, E32
                 E IMMUNOMEDIC/PA, CS
\Gamma8
             121 S E6-E20
L9
             183 S L7, L8 NOT L4
L10
               2 S L9 AND (F OR FLUORIN?)()18
L11
               0 S L9 AND F18
L12
             181 S L9 NOT L10
                 SEL RN L10
     FILE 'REGISTRY' ENTERED AT 17:42:03 ON 12 AUG 2002
L13
             85 S E1-E85
L14
              12 S L13 AND PROTEIN/FS
     FILE 'HCAPLUS' ENTERED AT 17:42:53 ON 12 AUG 2002
                 SET SMARTSELECT ON
L15
             SEL L12 1- RN : 751 TERMS
                 SET SMARTSELECT OFF
     FILE 'REGISTRY' ENTERED AT 17:42:59 ON 12 AUG 2002
            751 S L15
L17
            152 S L16 AND PROTEIN/FS
L18
            152 S L17 NOT L6, L14
              0 S L18 AND F/ELS
L19
             89 S L18 AND SQL<=10
L20
L21
             48 S L20 NOT MULTICHAIN/NTE
L22
             17 S L21 NOT (PHENYLALAN? OR HISTID?)
                                                                       Jan Delaval
              1 S L22 AND C56H63I2N11013
L23
                                                                    Reference Librarian
                                                                Biotechnology & Chemical Library
                E C56H63I2N11013/MF
                E GYWGKGYW/SQEP
                                                                   CM1 1E07 - 703-308-4498
L24
              1 S E3
                                                                    jan.delaval@uspto.gov
L25
              1 S L23, L24
L26
             89 S L18, L14, L6 AND S/ELS
L27
             77 S L26 AND 46.150.18/RID
L28
             77 S L27 AND NR>=2
L29
             57 S L28 AND NC4-C6/ES
L30
             13 S L29 NOT PHENYLALAN?
L31
              9 S L30 NOT PROL?
L32
              5 S L31 AND S>=2
                E CYS-TYR-TRP-GLY-CYS-GLY-TYR-TRP/SQEP
                E GLY-TYR-TRP-GLY-LYS-GLY-TYR-TRP/SQEP
```

SAV L25 NEON071247/A

FILE 'HCAPLUS' ENTERED AT 17:52:46 ON 12 AUG 2002

L33 1 S L25

1 S L33 AND L7, L8 L34

FILE 'USPATFULL, USPAT2' ENTERED AT 17:53:01 ON 12 AUG 2002 L35

=> fil reg

FILE 'REGISTRY' ENTERED AT 17:53:23 ON 12 AUG 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 11 AUG 2002 HIGHEST RN 443634-39-7 DICTIONARY FILE UPDATES: 11 AUG 2002 HIGHEST RN 443634-39-7

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sqide can 125

L25 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

253197-60-3 REGISTRY RN

D-Tryptophan, N-acetylglycyl-3-iodo-D-tyrosyl-D-tryptophylglycyl-N6-acetyl-CN D-lysylglycyl-3-iodo-D-tyrosyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: WO9966951 PAGE: 61 claimed protein

PROTEIN SEQUENCE; STEREOSEARCH FS

SQL 8

NTE modified

type		ocation	description					
terminal mod. modification modification modification	Gly-1 Tyr-2 Lys-5 Tyr-7	- - - -	N-acetyl iodo <i> acetyl<ac> iodo<i></i></ac></i>					

SEO 1 GYWGKGYW _____

HITS AT: 1-8

MFC56 H63 I2 N11 O13

SR

CA, CAPLUS, TOXCENTER, USPATFULL LC STN Files:

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

I

PAGE 2-A | OH

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:69307

=> fil hcaplus FILE 'HCAPLUS' ENTERED AT 17:53:31 ON 12 AUG 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Aug 2002 VOL 137 ISS 7 FILE LAST UPDATED: 11 Aug 2002 (20020811/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d all hitstr 134

```
L34 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS
```

AN 1999:819263 HCAPLUS

DN 132:69307

TI Use of bispecific antibodies for pre-targeting diagnosis and therapy

IN Hansen, Hans J.; Griffiths, Gary L.; Leung, Shui-On; McBride,
William J.; Qu, Zhengxing

PA Immunomedics, Inc., USA

SO PCT Int. Appl., 76 pp. CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K039-00

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 8, 9

FAN.CNT 14

	PAT	ENT	NO.		KI	ND	DATE			A	PPLI	CATI	N NC	0.	DATE			
ΡĮ	WO 9966951			Α	2	1999	1229		W	0 19	99 - U	S138	79	1999	0622			
	WO	9966	951		A3		20000615											
		W:	ΑE,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,
			DE,	DK,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,
			JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,
			MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,
			TM,	TR,	TT,	UA,	ŪG,	US,	UZ,	VN,	YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,
			MD,	RU,	ТJ,	TM												
		RW:	GH,	GM,	ΚE,	LS,	MW,	SD,	SL,	SZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,	DK,
			ES,	FI,	FR,	GB,	GR,	ΙĒ,	IT,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

```
AU 9945792
                       A1
                             20000110
                                            AU 1999-45792
                                                              19990622
     EP 1089766
                       A2
                             20010411
                                            EP 1999-928808
                                                              19990622
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2002518460
                        T2
                             20020625
                                            JP 2000-555637
                                                              19990622
PRAI US 1998-90142P
                        Ρ
                             19980622
     US 1998-104156P
                       Ρ
                             19981014
     WO 1999-US13879
                       W
                             19990622
OS
     MARPAT 132:69307
AB
     The present invention relates to a bispecific antibody or antibody
     fragment having at least one arm that specifically binds a targeted tissue
     and at least one other arm that specifically binds a targetable conjugate.
     The targetable conjugate comprises a carrier portion which comprises or
     bears at least one epitope recognizable by at least one arm of said bispecific antibody or antibody fragment. The targetable conjugate
     further comprises one or more therapeutic or diagnostic agents or enzymes.
     The invention provides constructs and methods for producing the bispecific
     antibodies or antibody fragments, as well as methods for using them.
ST
     immunotargeted drug delivery bispecific antibody diagnosis
ΙT
     Imaging agents
        (MRI; bispecific antibodies for pre-targeting diagnosis and therapy)
IT
     Diagnosis
        (agents; bispecific antibodies for pre-targeting diagnosis and therapy)
IT
     Chelating agents
     Drug targeting
     Genetic engineering
     Molecular cloning
     Radiotherapy
     Test kits
     Transcription initiation
     Transduction, genetic
         (bispecific antibodies for pre-targeting diagnosis and therapy)
     Fusion proteins (chimeric proteins)
IΤ
     RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU
     (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); PROC (Process); USES (Uses)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
IΤ
     Haptens
     RL: BPR (Biological process); BSU (Biological study, unclassified); PEP
     (Physical, engineering or chemical process); THU (Therapeutic use); BIOL
     (Biological study); PROC (Process); USES (Uses)
         (bispecific antibodies for pre-targeting diagnosis and therapy)
IT
     Chelates
     RL: FMU (Formation, unclassified); THU (Therapeutic use); BIOL (Biological
     study); FORM (Formation, nonpreparative); USES (Uses)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
     Carbohydrates, biological studies
IT
     RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
     use); BIOL (Biological study); PROC (Process); USES (Uses)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
IT
     Peptides, biological studies
     RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
     use); BIOL (Biological study); PROC (Process); USES (Uses)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
     Radionuclides, biological studies
     RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
     use); BIOL (Biological study); PROC (Process); USES (Uses)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
ΙT
     Antibodies
     RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU
     (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); PROC (Process); USES (Uses)
        (bispecific; bispecific antibodies for pre-targeting diagnosis and
```

therapy) Toxicity TΤ (drug; bispecific antibodies for pre-targeting diagnosis and therapy) IT Immunoglobulins RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (fragments; bispecific antibodies for pre-targeting diagnosis and therapy) IT Fissurella (hemocyanin of, conjugation of; bispecific antibodies for pre-targeting diagnosis and therapy) ΙT Antibodies RL: BPN (Biosynthetic preparation); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (humanized; bispecific antibodies for pre-targeting diagnosis and therapy) IT Drug delivery systems (immunoconjugates; bispecific antibodies for pre-targeting diagnosis and therapy) Enzymes, biological studies TΤ RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (immunoconjugates; bispecific antibodies for pre-targeting diagnosis and therapy) IT Drug delivery systems (immunotargeted; bispecific antibodies for pre-targeting diagnosis and therapy) IT Hemocyanins RL: RCT (Reactant); RACT (Reactant or reagent) (keyhole limpet, conjugation of; bispecific antibodies for pre-targeting diagnosis and therapy) TΤ Antibodies RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (monoclonal; bispecific antibodies for pre-targeting diagnosis and therapy) TΤ Circulation (nonlocalized antibody clearing from; bispecific antibodies for pre-targeting diagnosis and therapy) IT Drug delivery systems (prodrugs; bispecific antibodies for pre-targeting diagnosis and therapy) IT Epitopes (site-specific; bispecific antibodies for pre-targeting diagnosis and therapy) ΙT Milk Plant (Embryophyta) (transgenic protein prodn. in; bispecific antibodies for pre-targeting diagnosis and therapy) IT Animal Bacteria (Eubacteria) Insect (Insecta) Mammal (Mammalia) (transgenic; bispecific antibodies for pre-targeting diagnosis and therapy) ITEmbryo, animal (zygote, transduction of; bispecific antibodies for pre-targeting diagnosis and therapy) IT 9016-18-6D, Carboxylesterase, conjugates RL: BAC (Biological activity or effector, except adverse); BSU (Biological

```
study, unclassified); PEP (Physical, engineering or chemical process); THU
     (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
TΤ
     253197-60-3P
     RL: BPR (Biological process); BSU (Biological study, unclassified); PEP
     (Physical, engineering or chemical process); PNU (Preparation,
     unclassified); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); PROC (Process); USES (Uses)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
ΙT
     10098-91-6, Yttrium 90, reactions 14133-76-7, Technetium 99, reactions
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
ΙT
     249292-65-7DP, Bz-DTPA and thiosemicarbazonyloxyglyoxylcysteine conjugate
     253197-63-6P
                   253331-44-1DP, peptide conjugate
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
ΙT
     67-43-6, Dtpa
                    56491-86-2, Nota 60239-18-1, Dota 60239-22-7, Teta
     253197-61-4D, Thiosemicarbazonylglyoxylcysteine, derivs. and peptide
                  253197-62-5, Thiosemicarbazinylacetylcysteine
     conjugates
     RL: BPR (Biological process); BSU (Biological study, unclassified); NUU
     (Other use, unclassified); BIOL (Biological study); PROC (Process); USES
        (chelating agent; bispecific antibodies for pre-targeting diagnosis and
        therapy)
ΤТ
     7440-42-8, Boron, biological studies 14798-12-0, Boron 10, biological
     studies
     RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
     use); BIOL (Biological study); PROC (Process); USES (Uses)
        (irradn. of; bispecific antibodies for pre-targeting diagnosis and
        therapy)
IT
     253197-60-3P
     RL: BPR (Biological process); BSU (Biological study, unclassified); PEP
     (Physical, engineering or chemical process); PNU (Preparation,
     unclassified); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); PROC (Process); USES (Uses)
        (bispecific antibodies for pre-targeting diagnosis and therapy)
RN
     253197-60-3 HCAPLUS
CN
     D-Tryptophan, N-acetylglycyl-3-iodo-D-tyrosyl-D-tryptophylglycyl-N6-acetyl-
```

D-lysylglycyl-3-iodo-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

T

```
=> fil uspatall
FILE 'USPATFULL' ENTERED AT 17:54:00 ON 12 AUG 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 17:54:00 ON 12 AUG 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
=> d bib abs hitstr 135
L35 ANSWER 1 OF 1 USPATFULL
       2000:30637 USPATFULL
TI
       Chair floatation device
       Walker, Willette, 1104 Davis Dr., Tampa, FL, United States 33619
ΙN
ΡI
       US 6036563
                               20000314
       US 1998-90142
                               19980604 (9)
ΑI
DT
       Utility
FS
       Granted
EXNAM Primary Examiner: Basinger, Sherman
CLMN
       Number of Claims: 20
       Exemplary Claim: 1
ECL
DRWN
       4 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       A new chair floatation device for permitting a person, such as a child,
       to float comfortably in a body of water. The inventive device includes a
       hollow body member with a back wall portion forming a backrest, a seat
       portion, and a front wall portion. A pair of spaced apart leg holes
       extend through the front wall portion. A tray extends from the front
       wall and a pair of spaced apart armrests extend between the back wall
      portion and the front wall portion. A seat harness member 50 extends
      between the front wall portion 32 and the back wall portion 26 while a
      belt strap harness 60 is also coupled to the body member.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 253197-60-3P
        (bispecific antibodies for pre-targeting diagnosis and therapy)
```

D-Tryptophan, N-acetylglycyl-3-iodo-D-tyrosyl-D-tryptophylglycyl-N6-acetyl-

D-lysylglycyl-3-iodo-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

253197-60-3 USPATFULL

. •

RN

CN

PAGE 1-A

PAGE 1-B

Т